Results of the LMT81 protocol, a modified LSA<sub>2</sub>L<sub>2</sub> protocol with high dose methotrexate, on 84 children with non‐B‐cell (lymphoblastic) lymphoma

Catherine Patte(Institut Gustave Roussy), Jean Lemerle(Institut Gustave Roussy), Olivier Hartmann(Institut Gustave Roussy), Jean‐Michel Caillaud(Institut Gustave Roussy), Dominique Valteau‐Couanet(Université Paris-Saclay), C Bayle(Institut Gustave Roussy), F Flamant(Institut Gustave Roussy), C Kalifa(Institut Gustave Roussy), Laurence Brugières(Université Paris-Saclay)
Medical and Pediatric Oncology
January 1, 1992
10.1002/mpo.2950200204
Cited by 113

Related Papers

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|641
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge
|Journal of Clinical Oncology|2015|450
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
|Blood|2006|431
SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease
|Neuro-Oncology|2013|371
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
|Blood|2006|362